MedImpact Announces Early Settlement Date for Cash Tender Offer for 10.5% Senior Secured Notes due 2018

26 Oct, 2015, 13:42 ET from MedImpact Holdings, Inc.

SAN DIEGO, Oct. 26, 2015 /PRNewswire/ -- MedImpact Holdings, Inc. ("MedImpact") today announced that it has set the early settlement date for its previously announced cash tender offer (the "Offer") for any and all of its outstanding 10.5% Senior Secured Notes due 2018 (the "Notes").  As of 5:00 p.m., New York City time, on October 14, 2015 (the "Early Tender Time"), $389,000,000 aggregate principal amount of the Notes were validly tendered and not validly withdrawn in the Offer prior to the Early Tender Time, representing approximately 99.74% of all of the outstanding Notes.   

MedImpact has set October 27, 2015 as the early settlement date for those Notes that were validly tendered and not validly withdrawn in the Offer prior to the Early Tender Time.  Holders of Notes who validly tendered and did not validly withdraw Notes at or prior to the Early Tender Time will receive total consideration of $1,057.50 per $1,000 principal amount of Notes validly tendered and accepted for purchase, which includes an early tender payment of $30.00 per $1,000 principal amount of Notes, plus any accrued and unpaid interest relating to such purchased Notes up to, but not including, the early settlement date. 

The Offer will expire at 12:00 midnight, New York City time, at the end of October 28, 2015, unless extended or earlier terminated as described in the Offer to Purchase (such time and date, as they may be extended or earlier terminated, the "Expiration Time").  Subject to the terms and conditions of the Offer, Holders of Notes that are validly tendered after the Early Tender Time, but prior to the Expiration Time, and accepted for purchase will be entitled to receive the tender offer consideration of $1,027.50 per $1,000 principal amount of Notes validly tendered and accepted for payment, plus any accrued and unpaid interest relating to such purchased Notes up to, but not including, the final settlement date, which is expected to be promptly following the Expiration Time. Holders of Notes validly tendered after the Early Tender Time and accepted for purchase will not receive an early tender payment.

The Offer is being made on and subject to the terms and conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated September 30, 2015 (the "Offer to Purchase") and the related Letter of Transmittal.  MedImpact will not be obligated to accept for purchase any Notes pursuant to the Offer unless certain conditions are satisfied, or if applicable, waived by MedImpact, including MedImpact's arrangement on terms satisfactory to it of financing in an amount sufficient to fund the full amount necessary to purchase all Notes tendered prior to the Early Tender Time, including related fees and expenses.

In connection with the Offer, MedImpact also solicited consents for proposed amendments to the indenture under which the Notes were issued (the "Indenture") as described in the Offer to Purchase.  As previously disclosed, holders of the Notes validly tendered and not validly withdrawn in the Offer prior to the Early Tender Time constitute a majority of outstanding principal amount of the Notes, which is sufficient consent to the proposed amendments to the Indenture governing the Notes.  On October 19, 2015, MedImpact and the trustee executed a supplemental indenture to the Indenture which eliminates most of the restrictive covenants and certain events of default contained in the Indenture. The supplemental indenture, which is described in the Offer to Purchase, will become operative as of the early settlement date, upon settlement of the Notes validly tendered and not validly withdrawn in the Offer prior to the Early Tender Time as described above.  Holders of Notes outstanding following the date the supplemental indenture becomes operative will be subject to the terms of the supplemental indenture even though they did not consent to the amendments.

Assuming the above-described financing is arranged, MedImpact intends to redeem any Notes not purchased pursuant to the Offer in accordance with the Indenture, at the redemption price specified in the Indenture, which is currently 105.250% of the principal amount redeemed, plus any accrued and unpaid interest payable thereon up to, but not including, the redemption date. The Company intends to issue a notice of redemption to call for redemption all of the Notes that remain outstanding following consummation of the Offer. This press release shall not constitute, or be deemed to constitute, a notice of redemption of the Notes under the Indenture governing the Notes. 

UBS Investment Bank is acting as the dealer manager and solicitation agent, and D.F. King & Co., Inc. is the information agent and depositary, for the Offer and Solicitation. Requests for documentation should be directed to D.F. King & Co., Inc. at (800) 283-2170 (toll free) (banks and brokerage firms please call (212) 269-5550). Questions regarding the Offer and Solicitation should be directed to UBS Investment Bank at (888) 719-4210 (U.S. toll-free) or (203) 719-4210 (collect), attention: Liability Management Group.

None of MedImpact, its board of directors, the dealer manager, the information agent and depositary or the trustee for the Notes, or any of their respective affiliates, is making any recommendation as to whether holders should tender any Notes in response to the Offer.  Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of Notes to be so tendered.

This announcement is for information purposes only and does not constitute an offer to buy or the solicitation of an offer to sell securities.  The Offer is being made solely by means of the Offer to Purchase and the related Letter of Transmittal.  In those jurisdictions where the securities, blue sky or other laws require any tender offer to be made by a licensed broker or dealer, the Offer will be deemed to be made on behalf of MedImpact by the dealer manager or one or more registered brokers or dealers licensed under the laws of such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements, including, but not limited to, statements about the Offer, the terms of the Offer and the dates on which actions relating to the Offer are expected to occur, are based on current expectations, estimates, forecasts and projections based on management's judgment, beliefs, current trends and market conditions and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Accordingly, we caution you not to place undue reliance on these statements. Factors that could cause or contribute to such differences include, but are not limited to, MedImpact's ability to secure financing on terms acceptable to it and satisfaction or waiver of the other conditions of the Tender Offer contained in the Offer to Purchase. Detailed descriptions of other risks relating to the Offer and MedImpact are discussed in the Offer to Purchase and in the MedImpact 2014 Annual Report included in the Offer to Purchase.  We undertake no obligation to make any revision to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release.

SOURCE MedImpact Holdings, Inc.